for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Brickell Biotech Inc

BBI.N

Latest Trade

0.82USD

Change

0.04(+4.49%)

Volume

6,343

Today's Range

0.81

 - 

0.87

52 Week Range

0.72

 - 

4.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Brickell Biotech Announces Approval Of Sofpironium Bromide Gel, 5% In Japan For Treatment Of Primary Axillary Hyperhidrosis

Sept 25 (Reuters) - Brickell Biotech Inc <BBI.O>::BRICKELL BIOTECH ANNOUNCES APPROVAL OF SOFPIRONIUM BROMIDE GEL, 5% IN JAPAN FOR TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS RECEIVED BY ITS DEVELOPMENT PARTNER, KAKEN PHARMACEUTICAL.BRICKELL BIOTECH - JAPANESE DEVELOPMENT PARTNER, KAKEN PHARMACEUTICAL GOT APPROVAL TO MANUFACTURE, MARKET SOFPIRONIUM BROMIDE GEL, 5% IN JAPAN.BRICKELL BIOTECH INC - ON TRACK TO INITIATE ITS U.S. PIVOTAL PHASE 3 PROGRAM FOR SOFPIRONIUM BROMIDE IN Q4 2020.

Anges And Brickell Biotech Announce A Collaboration Agreement For The Development Of A Novel DNA Vaccine Candidate For COVID-19 In U.S.

Sept 8 (Reuters) - AnGes Inc <4563.T>::ANGES AND BRICKELL BIOTECH ANNOUNCE A COLLABORATION AGREEMENT FOR THE DEVELOPMENT OF A NOVEL DNA VACCINE CANDIDATE FOR COVID-19 IN THE U.S..BRICKELL BIOTECH INC - ANGES WILL CONTINUE TO LEAD DEVELOPMENT OF ITS VACCINE CANDIDATE IN JAPAN.BRICKELL BIOTECH INC - HAS RECEIVED RIGHT TO DEVELOP AND, IF APPROVED, COMMERCIALIZE ANGES' DNA VACCINE IN U.S. AND CERTAIN UNDERSERVED COUNTRIES..

Brickell Biotech Posts Q2 Loss Per Share Of $0.43

Aug 12 (Reuters) - Brickell Biotech Inc <BBI.O>::BRICKELL BIOTECH REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $600,000 VERSUS $2.6 MILLION.POSITIVE DATA FROM SOFPIRONIUM BROMIDE PHASE 3 PIVOTAL STUDY IN JAPAN PRESENTED IN Q2 2020 BY DEVELOPMENT PARTNER, KAKEN.KAKEN TO RECEIVE REGULATORY DECISION IN JAPAN FOR SOFPIRONIUM BROMIDE GEL AS EARLY AS Q4 OF 2020.BRICKELL PLANS TO INITIATE ITS U.S. PIVOTAL PHASE 3 PROGRAM IN Q4 OF 2020.QTRLY LOSS PER SHARE $0.43.

Brickell Biotech Posts Quarterly Loss Per Share $0.45

May 13 (Reuters) - Brickell Biotech Inc <BBI.O>::BRICKELL BIOTECH REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 REVENUE $1.0 MILLION VERSUS $3.5 MILLION.QTRLY LOSS PER SHARE $0.45.

Brickell Biotech Issues Prospectus Related To Resale Of Common Stock By Lincoln Park Capital Fund, Llc

April 3 (Reuters) - Brickell Biotech Inc <BBI.O>::BRICKELL BIOTECH - PROSPECTUS RELATES TO RESALE, FROM TIME TO TIME, OF UP TO 2.6 MILLION SHARES OF COMMON STOCK BY LINCOLN PARK CAPITAL FUND, LLC.

Brickell Biotech Q4 Revenue $700,000 Versus $2.5 Million

March 18 (Reuters) - Brickell Biotech Inc <BBI.O>::BRICKELL BIOTECH REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 REVENUE $700,000 VERSUS $2.5 MILLION.QTRLY NET LOSS WAS $10.9 MILLION VERSUS $3.7 MILLION.

Brickell Biotech Files Prospectus Relates To Offer, Sale By Selling Stockholder Of Up To 1.6 Million Shares

Feb 28 (Reuters) - Brickell Biotech Inc <BBI.O>::BRICKELL BIOTECH FILES PROSPECTUS RELATES TO OFFER, SALE FROM TIME TO TIME BY SELLING STOCKHOLDER OF UP TO 1.6 MILLION SHARES OF CO'S COMMON STOCK.

Lincoln Park Capital Fund Llc Reports 9.99% Passive Stake In Brickell Biotech

Feb 27 (Reuters) - Brickell Biotech Inc <BBI.O>::LINCOLN PARK CAPITAL FUND LLC REPORTS 9.99% PASSIVE STAKE IN BRICKELL BIOTECH INC AS OF FEBRUARY 20, 2020 - SEC FILING.

Brickell Biotech Announces Settlement Of Dispute With Bodor Labs And Entry Into Equity Funding Agreements

Feb 18 (Reuters) - Brickell Biotech Inc <BBI.O>::BRICKELL BIOTECH ANNOUNCES SETTLEMENT OF DISPUTE WITH BODOR LABS AND ENTRY INTO EQUITY FUNDING AGREEMENTS.BRICKELL BIOTECH INC - AS PART OF SETTLEMENT AND AMENDED LICENSE AGREEMENT, BRICKELL AGREED TO MAKE AN UPFRONT PAYMENT TO BODOR OF $1.0 MILLION IN CASH.BRICKELL BIOTECH - AGREED TO PAY FUTURE AMOUNTS, UP TO $1.0 MILLION IN CASH AND $1.5 MILLION IN COMMON STOCK, UPON ACHIEVEMENT OF SPECIFIED MILESTONES.BRICKELL BIOTECH INC - AGREED TO PAY BODOR A LOW SINGLE-DIGIT ROYALTY RELATED TO A NEWLY FILED PROVISIONAL PATENT APPLICATION.

Brickell Biotech Inc Files For Mixed Shelf Of Up To $75 Million

Feb 10 (Reuters) - Brickell Biotech Inc <BBI.O>::BRICKELL BIOTECH INC FILES FOR MIXED SHELF OF UP TO $75 MILLION – SEC FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up